The firm is an early-stage venture capital firm based in the United States and founded by experienced healthcare, life sciences, and technology executives. The firm invests globally in companies at the intersection of science, healthcare, and advanced computing, typically participating at the Seed stage with initial investments of approximately $250K–$500K and capacity for follow-on financings. The firm takes a hands-on investment approach and works closely with portfolio companies on strategy, business development, fundraising, and operational growth.  
 
The firm invests broadly across therapeutics, diagnostics, medical devices, and healthcare technologies, with a particular focus on artificial intelligence, machine learning, computational biology, data science, and advanced analytics. Areas of interest include AI-enabled drug discovery, clinical development, precision medicine, diagnostics, and technologies that improve healthcare delivery and operations. The firm is particularly interested in opportunities where software, computational approaches, and proprietary data can create meaningful advantages in the discovery, development, or delivery of healthcare solutions.  
 
From a company and management team perspective, the firm seeks ambitious founders developing differentiated technologies with meaningful commercial potential. The firm values domain expertise and experienced management teams but also places significant emphasis on scientific innovation, technological differentiation, and the potential to build scalable businesses. The firm may act as either a lead investor or co-investor and provides active support to help portfolio companies achieve key development, financing, and commercial milestones. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital arm of a global pharmaceutical company invests in early-stage healthcare innovation. The firm primarily targets Pre-Seed and Seed financings, with initial investments generally ranging from approximately $500K to $2M. The firm evaluates opportunities globally, with a particular focus on companies based in the United States. The firm is open to both leading and co-investing and may seek board representation when serving as the lead investor. While primarily financially driven, the firm can also leverage the strategic capabilities and resources of its affiliated pharmaceutical organization when relevant to a portfolio company. 

The firm seeks innovative science addressing significant unmet medical needs, with a primary focus on therapeutics and technologies enabling therapeutic development. Modalities and technologies of interest include cell and gene therapies, small molecules, radiopharmaceuticals, CRISPR and other gene-editing approaches, and data-driven technologies such as AI-enabled drug discovery. Key therapeutic areas include oncology, neurology, and rare diseases. The firm may also selectively consider less-invasive diagnostic technologies. The firm primarily targets companies with programs ranging from preclinical development through Phase I. 

From a company and management team perspective, the firm prioritizes promising science supported by strong and defensible intellectual property. As an active investor, the firm supports portfolio companies through its industry network, investment expertise, and broader strategic resources. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global pharmaceutical company pursues external innovation through in-licensing, strategic partnerships, and other business development relationships with biotechnology and pharmaceutical companies. The firm evaluates opportunities globally and seeks differentiated therapeutic assets that can complement and expand its existing development and commercial portfolio. 

The firm is primarily focused on oncology and neuroscience, with particular interest in hematologic malignancies, solid tumors, and sleep disorders. Additional areas of interest include pediatric oncology, select central nervous system disorders, and rare diseases, particularly conditions affecting pediatric populations. The firm generally prefers therapeutic assets that have demonstrated proof-of-concept in humans, although earlier-stage programs may be considered when they demonstrate particularly strong strategic alignment in the firm’s core areas of oncology or sleep medicine. 

From a company and management team perspective, the firm seeks partners developing differentiated therapeutics with compelling scientific rationale, meaningful clinical potential, and the ability to address significant unmet medical needs. The firm is flexible regarding company geography and evaluates partnership opportunities based primarily on the quality of the underlying asset, clinical evidence, strategic fit, and potential to complement its therapeutic expertise and global development capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A strategic investment arm of a global consumer health and personal care company with a long-standing presence has made strategic investments for several years and typically deploys approximately $500K–$2M as an initial investment in companies that complement its existing businesses and long-term innovation priorities. The firm evaluates opportunities globally and combines financial investment with potential access to its parent company’s research, commercial, supply chain, and international market capabilities. 

The firm primarily focuses on therapeutics and drug discovery technologies addressing dermatology, skin-related diseases, aging, and longevity. The firm invests in both preclinical and early clinical-stage companies and seeks differentiated science with the potential to address meaningful needs in skin health and adjacent areas. Medical devices, diagnostics, and digital health are not current investment priorities, although the firm may selectively consider enabling technologies with strong strategic relevance to its core healthcare, personal care, or related innovation activities. 

From a company and management team perspective, the firm seeks compelling technologies with clear strategic relevance, scalability, and the potential for collaboration with established global brands. The firm is particularly interested in opportunities that can leverage its broader R&D, consumer, supply chain, and commercialization capabilities. Investments may involve minority equity positions alongside strategic collaborations, with the firm emphasizing opportunities where it can provide meaningful value beyond financial capital. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.